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oslyn and Stony Brook, New York
ver the past 40 years, progress in understanding hypertro-
hic cardiomyopathy (HCM) has been driven in large part
y echocardiography, beginning with depiction of the
echanism of left ventricular (LV) outflow tract obstruction
1,2). However, application of cardiac magnetic resonance
maging (CMR) to HCM began over 20 years ago, initially
or conventional 2-dimensional morphology and function,
ater for myocardial strain and its relationship to hypertro-
hy (3–5). Recently, CMR has confirmed early observations
ade with positron emission tomography on microvascular
ysfunction in HCM and its potential prognostic signifi-
ance (6,7). More importantly, with the application of
elayed hyperenhancement (DHE) imaging for detection of
brosis in HCM, CMR has begun to change the paradigm
n our understanding of determinants of HCM outcomes
7–9). In this issue of the Journal, Olivotto et al. (10) add
nother chapter to this story, demonstrating the impact of
MR 3-dimensional LV volumetric assessment, in this case
ocused on LV mass index, on the prognosis in HCM (9).
See page 559
Conventionally, the diagnostic echocardiographic marker
or HCM has been an unexplained increase in LV wall
hickness, and a markedly increased maximal LV wall
hickness has been linked to the risk of sudden death (11).
owever, in some patients, isolated anterolateral LV free wall
r apical hypertrophy eludes transthoracic 2-dimensional
chocardiography but is easily detected by CMR (5). More
ecently, the role of CMR DHE has emerged with Moon et
l. (8) demonstrating that the presence and severity of
yocardial fibrosis by CMR DHE was related to progres-
ive LV dilation and markers of risk for sudden death, while
dabag et al. (9) showed that DHE was associated with a
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
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ights into the significance of DHE have surfaced in recent
bstract presentations and are likely to appear in full
ublications in the near future. In addition, microvascular
ysfunction demonstrated by CMR first-pass stress perfu-
ion imaging appears to be associated with DHE fibrosis,
hich may explain, in part, the association of microvascular
ysfunction with poor prognosis in HCM (6,7). In contrast,
he role of CMR analyses of LV hypertrophy in clinical risk
ssessment in HCM has received little attention. Olivotto et
l. (10) have now rectified this situation by examining the
elationship between CMR LV mass index and adverse
utcomes, as well as the relative utility of 2-dimensional
chocardiographic LV wall thickness and CMR LV mass
ndex as clinical markers and predictors of adverse outcomes
n a well-powered multicenter HCM study (9). Two-
imensional echocardiographic LV mass is known to be
naccurate in HCM due to the variability of wall thickness,
ut this limitation is easily overcome by CMR, which provides
ccurate and reproducible assessment of 3-dimensional LV
ass independent of geometric assumptions.
The 4 participating centers studied 264 HCM patients
age 43  18 years; 197 men) with a mean follow-up of
.6  0.7 years, while 606 healthy control subjects were
rovided by the Framingham Heart study. The investigators
howed that 56 (21%) of the patients had normal CMR LV
ass indexes despite echocardiographic segmental wall
hickening diagnostic of HCM. While the relationship
etween LV wall thickness and LV mass index achieved
tatistical significance, the correlation was weak. Mortality
ata demonstrated that a markedly increased LV mass index
as a more sensitive correlate of cardiac mortality (100%
ensitive vs. 41% for echocardiographic wall thickness)
hile a markedly increased LV wall thickness had greater
pecificity for HCM-related mortality (90% vs. 39% for
MR LV mass index). These data indicate that yet another
omponent of the CMR examination may have an impor-
ant role to play in the evaluation of patients with HCM.
There are a few limitations to the current work. The
umber of cardiac deaths in the study was small, so that
onfirmation of the results is needed. Furthermore, the
nclusion of several deaths after septal myomectomy is
ebatable. No core laboratory for CMR quantitation was
sed, and the comparability of results from various partici-
ating centers is unclear. The normal control population
as not matched to the HCM population with regards to
ge and gender, which are known to affect LV structure and
unction. Finally, like most other reports on CMR in
CM, this one addresses only 1 facet of the multifaceted
MR examination. An integrated CMR appraisal, combin-
ng LV structure and function, LV outflow obstruction
everity, stress perfusion imaging, and DHE assessment of
brosis is badly needed so that the contribution of each of
hese important facets of this complex disorder to outcomes
an be better understood.
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Editorial Comment August 12, 2008:567–8Nonetheless, this study advances our current understand-
ng of HCM and of the role of CMR in assessing HCM at
ultiple levels. It makes a compelling argument against the
opular belief that global LV hypertrophy is a necessary
oncomitant of diagnosable HCM and underscores the
ncremental value of CMR LV mass index in the assessment
f HCM over and above conventional 2-dimensional echo-
ardiographic results. Thus, Olivotto et al. (10) have intro-
uced a conceptually strong application of CMR that aids
ur understanding and can improve our approach to risk
tratification in HCM. In the future, larger scale, longer-
erm prospective trials with well-matched control subjects
nd comprehensive CMR studies and data analysis will be
eeded to determine the ultimate role of CMR in HCM
ssessment.
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